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Abstract 
The reputation of the field of psychiatric genetics has recently become tarnished in the view of many 
human geneticists. Too many linked loci were claimed and withdrawn, too many association studies 
published and not confirmed, and, more recently, too many new and different chromosomal regions 
have been implicated for the same disorder. Here, we summarize recent trends, focusing on research 
that moves away from traditional linkage studies. Some promising strategies include psychophar-
macogenetics and consideration of endophenotypes such as neurophysiological and behavioral mark-
ers in addition to the clinical diagnosis. Utilization of rapid and automated methods for scoring genetic 
variants in large-scale association studies followed by multivariate analyses, which include environ-
mental as well as genetic data, will likely fare better than traditional linkage analysis in disentangling 
the complex genetics of psychiatric disorders. Some notable areas of recent progress include quanti-
fication of the genetic complexity of autism, identification of genetic variants protecting individuals 
from alcoholism, and the description of several polymorphisms likely to be relevant to behavior and 
psychiatry. The most notable example may be a common variant that affects the transcription rate in 
the promoter for the serotonin transporter gene that may be relevant for individual differences in the 




Recent advances in molecular genetics and the unprecedented developments in biotech-
nology have inspired tremendous optimism that we will soon know a few genes involved 
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in susceptibility to psychiatric disorders and individual differences in normal human be-
havior. Nevertheless, in contrast to some other complex disorders, no susceptibility loci for 
psychiatric disorders have been unambiguously identified. This is especially disappoint-
ing given the overwhelming epidemiological evidence that susceptibility to psychiatric 
disorders has a substantial genetic component. Concordance rates among monozygotic 
(MZ) twins for schizophrenia, bipolar disorder (also known as manic depression), alcohol-
ism, and Tourette syndrome are ∼50%. Short reviews of the epidemiological and genetic 
data for the most common psychiatric disorders are given in a recent summary prepared 
by a National Institute of Mental Health working group (1). Here we discuss the reasons 
for this relative lack of progress, including diagnostic problems and genetic complexity, 
and outline novel approaches likely to bemore successful. Since animal models will be dis-
cussed elsewhere in this issue (2), we will not discuss them here, although they are likely 
to have a key role in identifying interesting candidate genes. 
 
Epistatic Interaction of Genes and Multigenic Inheritance 
 
The transmission patterns of psychiatric disorders are undeniably complex. It is likely that 
a variety of genetic as well as environmental pathways can increase one’s susceptibility to 
a given psychiatric disorder. This is the concept of equifinality, where different initial con-
ditions can lead to the same endpoint (3). Although genetic heterogeneity is generally ac-
cepted to be a complicating issue for psychiatric disorders, it is not an insurmountable 
problem for gene identification. An instructive example is that of hearing loss, where >50 
loci have been mapped and about a dozen have been identified (4,5). 
In addition to heterogeneity, it is anticipated that to increase risk for many complex 
disorders, multiple deleterious genetic variants are required in combination. This is called 
multiplicative, epistatic, oligogenic, or multigenic inheritance (6–8). Such inheritance is in-
dicated when the risk to very close relatives of those affected is high but decreases rapidly 
in more distant relatives, as is observed in both schizophrenia (7) and bipolar disorder (9). 
To date, autism provides the best evidence for this type of multigenic inheritance. The MZ 
twin concordance rate for autism is close to 100%, yet the dizygotic rate is only 2–10%, 
suggesting that more than three interacting genes are involved [see also the review on the 
genetics of autism in this issue (10)]. Risch et al. (11) conducted a genome scan on sibs with 
autism and came to the stunning conclusion that increased allele sharing is observed over 
virtually every chromosomal region. These data are best explained if autism is caused by 
the interaction of >20 different loci, each with a minor effect. Such loci will be extremely 
difficult to identify and are expected to be quite common, such that everyone probably 
carries a few “autism alleles.” 
 
Diagnostic Problems and Pleiotropy: What a Microdeletion Syndrome Can Reveal 
about Psychiatric Disorders 
 
Although diagnoses for psychiatric disorders are obtained by clinical interview rather than 
by laboratory tests, they are not completely subjective. Psychiatrists have for decades used 
structured algorithms to aid in diagnosis. These algorithms are described in Diagnostic 
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and Statistical Manuals (DSMs) that have been extensively tested and revised to improve 
their reliability and validity, with DSM-IV being the current version (12,13). These struc-
tured diagnostic criteria were developed to provide homogeneous groups for both biolog-
ical and treatment studies. However, in the context of psychiatric genetics, it is not clear 
that these diagnostic categories have any relationship to genetic etiology. For example, a 
debate continues on whether bipolar disorder and schizophrenia are clearly distinct disor-
ders or part of a spectrum, and recent latent class analysis suggests that the reality is more 
complex than either view (14). 
Co-morbidity is another important complicating issue. Many psychiatric disorders of-
ten co-occur, such as substance-abuse disorders with mood and anxiety disorders (15). 
Such relationships among disorders may be explained by: (i) one of the disorders causing 
the other secondarily (e.g., depression → alcoholism, or vice versa); or (ii) one biological 
system affecting both traits [pleiotropy, e.g., dependence on marijuana, alcohol, and nico-
tine (16)]. An illustrative and rather sobering example of how diagnostic categories may not 
accurately reflect the underlying genetic condition is velocardiofacial syndrome (VCFS). This 
syndrome is usually caused by a specific deletion of ∼3 Mb on chromosome 22q11 and is 
associated with severe cognitive and behavioral problems (17). Individuals with VCFS are 
often diagnosed with a co-morbid psychiatric disorder, such as schizophrenia, bipolar dis-
order, major depression, attention deficit hyperactivity disorder (ADHD), or even autism 
(18–20).We can conclude that at least some genetic defects predispose to forms of psychi-
atric illness that do not fall neatly into a clearly defined DSM-IV category. In a few patients 
with schizophrenia lacking other hallmark features of VCFS, 22q11 deletions have been 
detected (21,22). Therefore, 22q11 is actively studied worldwide, and some positive linkage 
findings for schizophrenia and bipolar disorder have been reported (23–25). 
One gene in the critical 22q interval deleted in VCFS deserves special mention: COMT, 
which codes for catechol-O-methyltransferase, an enzyme involved in neurotransmitter 
metabolism. There are two forms of the enzyme differing at amino acid 158: one has high 
enzymatic activity, the other low. These two variants are found at about equal frequencies 
in Caucasians (26) and have been studied in patient samples with a variety of psychiatric 
disorders (Table 1). If hemizygosity for COMT was responsible for some of the psychiatric 
features of VCFS, having the low-activity form of COMT opposite a deletion would be 
predicted to be the most detrimental. Indeed, several studies support the involvement of 
COMT in rapid cycling bipolar disorder in VCFS patients (27,28). 
 
Linkage Studies for Psychiatric Disorders Continue to Be Confusing 
 
Because of their power to localize loci for classic Mendelian disorders, linkage studies have 
been the workhorse of disease gene-mapping studies. Loci for many complex disorders, 
such as Alzheimer’s disease or many cancers, have first been pinpointed by linkage anal-
ysis (29,30). Based on these successes, both traditional and sib-pair linkage studies for psy-
chiatric disorders have been performed, both in larger populations and in many different 
isolated populations in which there may be less heterogeneity due to a founder effect. 
These studies have recently been extensively reviewed and are not discussed further here 
(25,31–33). The more consistent, although not uncontested, loci are on chromosomes 6, 8, 
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13, and 22 for schizophrenia, and 4, 18, 21, and X for bipolar disorder. However, as dis-
cussed by Gershon (8), even when linkage is not initially replicated, the positive result does 
not need to be discarded: if the statistical power to find one particular locus under realistic 
assumptions is only ∼5–10%, most studies of similar size should not be expected to repli-
cate a correct original linkage. This fact makes the existing body of linkage results difficult 
to judge because many of the nonreplications may be due to insufficient statistical power, 
not because the linkage was not real. 
Alcoholism is another psychiatric disorder that continues to be the subject of substantial 
genetic analysis. For example, Lappalainen et al. (34) found both linkage and association 
of a rather narrowly defined alcoholism phenotype (with early onset and antisocial behav-
ior) in a population isolate in Finland to an allele of the serotonin receptor HTR1B. Perhaps 
the most ambitious effort to map alcoholism susceptibility genes is the Collaborative Study 
on the Genetics of Alcoholism (COGA). Initiated in 1989 by the National Institute on Alco-
hol Abuse and Alcoholism (NIAAA), COGA involves six research centers across the USA. 
The COGA group recently published a very large (>900 individuals) sib-pair linkage study 
on alcohol dependence (35). Although this is by far the most extensive study, the linkage 
results have been somewhat disappointing; although linkage to chromosomes 1, 7, and 
possibly 2 and 4 was implicated, none of these loci reached a truly convincing single locus 
P value. However, another group (36) studying a southwestern American Indian popula-
tion found evidence for linkage on 4p overlapping the region identified in the COGA study 
near the ADH gene cluster, discussed later as a candidate gene. 
 
Endophenotypes or Trait Markers—Are They Better than Clinical Diagnosis? 
 
Concordance for psychiatric illness among MZ twins is usually ∼50%, indicating a sub-
stantial role for the environment or chance. In addition, as discussed earlier, many psychi-
atric disorders are caused by multiple genes that interact. Both facts predict that having 
just one predisposing allele does not imply high risk; in fact, the majority of carriers are 
not expected to express any clinical phenotype. How, then, can carriers for genetic linkage 
studies be identified? Some predisposing alleles might be found through a definable inter-
mediate domain, e.g., neurophysiology. The basic idea of endophenotypes, or trait mark-
ers, is to find a trait that is more common in affected individuals than in the general 
population but also displayed often by unaffected relatives, marking these individuals as 
carriers of one of the predisposing alleles. Such a trait should be heritable, frequent in 
“high-risk” subjects (parents, siblings, or offspring), stable over one’s lifetime, and unaf-
fected by medication use (37). Several potential traits have recently been identified. A low 
response to alcohol is common in offspring of alcoholics and is predictive of future alco-
holism (38). Holzman et al. (39) have long advocated that a deficit in smooth pursuit eye 
tracking—present in 50–80% of patients with schizophrenia, 40% of their first-degree rela-
tives, but also 8% of the general population—is a marker for schizophrenia susceptibility 
genes. Recently, tentative linkage to this trait has been found on 6p, near a region previ-
ously implicated for schizophrenia (40). Freedman et al. (41) have described an electro-
physiological deficit, decreased P50 inhibition, that is common (∼10%) in the general 
population but is associated with schizophrenia in ∼50% of patients. Linkage of this P50 
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or a related deficit in families with schizophrenia has been reported on chromosomes 15 
and 22 (41,42), with greater LOD scores than with schizophrenia alone. A different electro-
physiological trait marker is the amplitude of the event-related potential called P3 or P300, 
which is associated with alcoholism (43), conduct problems (44), and other psychiatric ill-
nesses (45). The fact that this particular trait is not specific to alcoholism or schizophrenia 
does not disqualify it for genetic studies—since there is diagnostic overlap and co-morbid-
ity, some alleles are expected to be more general predisposing factors. Linkage analysis of 
the P3 amplitude in families with alcoholism resulted in significant linkage on other chro-
mosomal regions than when alcoholism alone was considered (35,46). Variance component 
analysis, in which both alcoholism and P3 amplitude were considered jointly, improved 
the evidence for linkage to a chromosomal region, 4p, known to contain protective candi-
date genes (47). 
Behavioral traits, such as temperament, appear to be another set of potential markers 
of interest in psychiatric genetics. Although these traits are further removed from the ge-
netic level than are physiological measures, they are easily testable and quantifiable, and 
there is a vast amount of literature linking temperament to biology (48). Cloninger et al. 
(49) argue that different personality disorders are associated with unique profiles of tem-
perament traits. Similarly, anxiety and neuroticism scores are higher in depressed individ-
uals than in the general population (50). A variety of studies also suggest that milder, 
nonpathological abnormalities in behavior are present in the parents of autistic children 
and thus may be markers for some of the many predisposing genes for autism (51). In the 
case of ADHD, a segregation analysis indicates that ADHD is best viewed as the extreme 
of a continuum, rather than a distinct disorder (52). Furthermore, genetic predisposition to 
a point on this continuum may be more or less pathological when expressed in different 
contexts. For example, an individual with hyperactive traits and a short attention span may 
excel if he or she is on a stand-up comedy stage but may not in a standard chemistry lec-
ture. 
 
Candidate Genes—The More the Merrier? 
 
Association studies with candidate genes remain conceptually the simplest genetic studies. 
They are popular because specific biological hypotheses can be tested in a design similar 
to a classical case-control study. However, a few caveats must be considered when inter-
preting the results of these seemingly simple studies. First, any attractive candidate gene 
is studied by a large number of laboratories, and there is clearly publication bias toward 
positive findings. Secondly, population stratification can result in false-positive associa-
tions that persist even when larger samples are studied. To overcome this problem, newer 
statistical tests have been developed, most of which use family (parents or discordant sib-
lings) rather than population controls. These tests have recently been reviewed (53–55). 
Currently, the best candidate alleles (since we all carry the same genes, it is the different 
alleles that are candidates) fulfill at least two criteria: (i) the variant has been shown to be 
functional (at the transcription or enzyme activity level, for example); and (ii) the variant 
has a high likelihood of being biologically relevant. Table 1 presents some currently stud-
ied candidate genes; not all of them are functional. 
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Table 1. Candidate genes of recent interest in psychiatric genetics 
Gene Variant(s) Disorder (or endophenotype) Citations 
5-HT transporter 
   SLC6A4 
Promotor VNTR 
   (5-HTTLPR), 2nd 
   intron VNTR 
Bipolar, MDD, OCD, compulsive 
   buying, temperament, substance 
   dependence, schizophrenia, 
   anxiety, Alzheimer’s, SAD, 
   psychoses, generalized social 
   phobia, alcohol tolerance 
61,84–102 
Tryptophan 5-mono- 
   oxygenase (TPH; 
   EC 1.14.16.4) 
Intronic RFLP Bipolar, MDD 90,103,104 
Monoamine oxidase 
   (MAO; EC 1.4.3.4) 
EcoRV RFLP, 
   promoter-VNTR 
Tourette syndrome, substance 
   abuse, OCD, mood disorders 
105–107 
5-HT receptor 1B 
   (HTR1B) 
HincII RFLP Antisocial alcoholism 34 
5-HT receptor 2A 
   (HTR2A) 
HpaII RFLP102T/C 
   promotor 
MDD, Alzheimer’s, schizophrenia, 
   generalized social phobia 
90,98,100,108 
5-HT receptor 2C 
   (HTR2C) 
Cys23Ser MDD, Alzheimer’s 90,98 
5-HT receptor 6 (HTR6) 267C/T Schizophrenia 109 
5-HT receptor 7 (HTR7) 2nd intron C/T Autism 110 
DA-β-hydroxylase 
   (DBH; EC 1.14.17.1) 
Ala304Ser Bipolar I, schizophrenia 111,112 
DA receptor D1 (DRD1) RFLP Bipolar 113 
DA receptor D2 (DRD2) Ser311Cys Bipolar, schizophrenia, alcoholism 88,113–115 
DA receptor D3 (DRD3) MspI RFLP, BalI 
   RFLP, MscI RFLP 
Tourette syndrome, substance 
   dependence, schizophrenia, 
   bipolar 
93,113,116–118 
DA receptor D4 
   HUMD4C (DRD4) 
VNTR, 48 bp direct 
   repeat 
Temperament, bipolar, MDD, 
   schizophrenia, psychoses 
84,88,90,119,120 
DA receptor D5 (DRD5) Microsatellite 
   (DRD5-M), (TC)n 
   promotor repeat 
Schizophrenia, bipolar 121 
DA transporter 
   (SLC6A3) 
DAT1 VNTR in 
   3′-untranslated 
   region 
Bipolar, MDD, alcohol withdrawal, 
   ADHD 
88,90,122,123 
Tyrosine hydroxylase 
   (TH; EC 1.14.16.2) 
VNTR intron I Alcohol-withdrawal delirium, bipolar 124,125 
Catechol-O-methyl- 
   transferase (COMT; 
   EC 2.1.1.6) 
158G/A ADHD, schizophrenia, MDD, OCD, 
   bipolar 
90,106,126–131 
NE transporter 
   (pSLC6A2) 
1287G/A MDD, Tourette syndrome 132,133 
γ-aminobutyric acid, 
   GABAA receptor α1 
GABRA1 Mood disorders 120,134 
μ-opioid receptor 
   (OPRM1) 
118A/G Alcohol dependence, alcohol 
   withdrawal 
135–138 
δ-opioid receptor 
   (OPRD1) 
921T/C Substance dependence 139 
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Table 1. Continued 
Gene Variant(s) Disorder (or endophenotype) Citations 
Cytochrome P-450 
   (CYP2E1) 
RFLP Excessive alcohol consumption 140,141 
KCNN3, SCA1, SCA6, 
   hSKCa3 
Trinucleotide 
   expansions 
Schizophrenia 142–149 
5-HT, serotonin; DA, dopamine; NE, norepinephrine; OCD, obsessive-compulsive disorder; MDD, major 
depressive disorder; SAD, seasonal affective disorder; ADHD, attention deficit and hyperactivity disorder 
 
Since its discovery in 1996 (56), a serotonin transporter promoter polymorphism (5-
HTTLPR) has been cited in >100 publications searching for association with traits ranging 
from compulsive buying through depression to alcoholism (Table 1). The alleles are caused 
by a 44 bp insertion/deletion ∼1 kb upstream of the serotonin transporter gene (SLC6A4), 
with homozygosity for the short variant resulting in less transcript and less protein expres-
sion (56,57). Low levels of serotonin degradation products in the cerebrospinal fluid of ag-
gressive and/or suicidal men or monkeys is among the most replicated physiological findings 
in psychiatry. Furthermore, some mutations in components of the serotonin pathway 
cause impulsive-aggressive behavior in patients or mice (reviewed in refs 58–60). Figure 1 
presents a diagram of a serotonergic synapse containing several components that have ge-
netic variants thought to be likely candidate genes for psychiatric disorders. Although 
most findings of associations with 5-HTTLPR to date, including an initial association with 
the personality trait neuroticism (57), have not been replicated (61–63), studies are contin-





Figure 1. A serotonergic synapse showing components that have genetic variants thought 
to be likely candidate genes for psychiatric disorders. The first important step in serotonin 
(5-HT) synthesis is the uptake of tryptophan (Trp) into the presynaptic cell. The conver-
sion of Trp to 5-hydroxytryptophan (5-HTP) is catalyzed by tryptophan hydroxylase 
(TPH). Aromatic amino acid decarboxylase (AADC) then converts 5-HTP to 5-HT, which 
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is subsequently released into the synapse. Once released, 5-HT may bind to post-synaptic 
receptors (e.g., 5-HT2A, 5-HT2C) or pre-synaptic autoreceptors (5-HT1B, 5-HT1A) or be 
removed from the synapse via the 5-HT transporter (SERT). Following re-uptake, 5-HT 
may be inactivated by monoamine oxidase (MAO) and then further oxidized to 5-hydroxy-
indoleacetic acid (5-HIAA). Measures of 5-HIAA in the cerebrospinal fluid (CSF) are often 
used to index serotonergic system function. 
 
In addition to 5-HTTLPR and COMT discussed earlier, DRD4 deserves a special men-
tion. This dopamine receptor binds clozapine, a widely used medication for the treatment 
of schizophrenia. A highly variable 48 bp (16 amino acid) repeat is present in 2–10 copies 
at the C-terminal, cytoplasmic end of this G-protein-coupled receptor (64). Two studies 
reported that the longer forms are associated with higher “novelty/sensation seeking” scores 
(65,66), but these findings have not been replicated (67–69). However, given that even 
within each repeat there are several variants, perhaps only certain ones are associated with 
novelty seeking (70). 
The most robust of all reported allelic variations relevant for psychiatric disorders is 
the association between the ADH/ALDH cluster on 4p and alcoholism. In linkage studies 
in two different populations, independent evidence for 4p was found (see above), and as-
sociation was found both in an Asian (71) and a European (72) population. The biological 
relevance of this genetic influence of variation in the alcohol metabolism pathway on 
drinking behavior has been known for many years. Following ingestion, alcohol is con-
verted, in the liver, by alcohol dehydrogenase (ADH) to acetaldehyde, which is then con-
verted by aldehyde dehydrogenase (ALDH) to acetate. Genetic variants that have a 
protective effect on the development of alcoholism include a high-activity isoform of ADH 
(ADH2*2) and a low-activity isoform of ALDH (ALDH2*2) (71). For individuals with 
ALDH2*2 (especially homozygotes, primarily people of Asian descent), ingestion of alco-
hol produces a “flushing” response that is characterized by increased blood flow to the 
skin of the face, neck, and chest and may include nausea, tachycardia, hypotension, and 
headache. These effects are thought to be due to a build-up of acetaldehyde in the blood. 
Initially, reports of candidate gene association studies consisted of testing the effects of 
alleles one at a time. More recently, potential epistatic interactions have been explicitly 
examined by testing for the effects of two markers and their statistical interaction. In these 
analyses, diagnoses are not the phenotypes of interest; rather, some continuously distrib-
uted endophenotype such as temperament is the dependent variable (73,74). This kind of 
analysis makes sense when the markers studied are known to belong to interacting systems 
and when the phenotype is thought to be oligogenic. Novel techniques such as single nu-
cleotide polymorphisms (SNPs) scored on DNA chips are likely to revolutionize associa-
tion studies by allowing for simultaneous testing of possibly thousands of candidate genes 
(75–77). Of course, the number of comparisons made must be considered, but this does not 
represent an insurmountable problem (78). In addition, it must be appreciated that the sta-
tistical power to detect interaction effects with a given sample size is much less than the 
power to detect main effects (79), so large samples are required for such analyses. 
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Psychopharmacology Informed by Genetics? 
 
One of the primary goals of psychiatric genetics is to further the development of psycho-
pharmacological agents. Psychopharmacogenetics may improve patient care by helping 
the clinician to individualize a patient’s treatment plan based on the individual’s genotype 
at some informative genetic marker (80,81). For example, individuals suffering from major 
depression, obsessive-compulsive disorder, or several other psychiatric disorders respond 
favorably to selective serotonin reuptake inhibitors (SSRIs) (e.g., Prozac). However, ∼30% 
of patients do not improve on SSRIs. Two reports from Italy suggest that nonresponders 
may be individuals who are homozygous for the low-activity form of 5-HTTLPR (82,83). 
If confirmed, and this is an important “if,” genetic testing of millions of patients may be-
come reality soon. Since many psychiatric conditions are associated with an increased su-




As we enter the new millennium, the field of psychiatric genetics is experiencing a para-
digm shift. Linkage analyses continue to be largely disappointing—even though some loci 
can be confirmed, positional cloning is considered an unlikely route to identify genes in-
volved in most psychiatric disorders. Co-morbidity and diagnostic uncertainties continue 
to plague the field. The realization that many susceptibility alleles will be common variants 
rather than rare mutations makes necessary new approaches to the design, analysis, and 
interpretation of psychiatric genetic studies. Two new directions emerge from these facts: 
(i) the genetic study of endophenotypes, i.e., phenotypes associated with a psychiatric ill-
ness that are more quantifiable, more common, and often associated across a wider spec-
trum of disorders; and (ii) genetic studies that are candidate gene driven rather than 
disorder driven. Candidate genes are surveyed for variants, and when a promising gene 
variant is identified that is both biologically relevant and has proven functional signifi-
cance, it is tested across the whole spectrum of psychiatric illness and endophenotypes, 
and for psychopharmacogenetic relevance. With new emerging techniques such as SNP 
analysis on DNA chips, these types of studies are predicted to increase. Although in this 
review we have barely touched on recent advances in statistical analyses, they are the 
lenses through which we examine heredity-behavior relationships. The inclusion of covari-
ates and the examination of interactions, both gene-gene and gene-environment, will be 
necessary in the development of a more complete understanding of the etiology of psychiat-
ric disorders. Although there is a tremendous amount of work ahead, we remain cautiously 
optimistic that genetic studies will clarify the complex roles of genes and environment in 
the etiology of psychiatric disorders. 
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